Vectors for enhanced expression of vegf for disease treatment
CA 2448132 A1 · Owner: Visser, Tjerk Johannes Anske · Inventors: Visser, Tjerk Johannes Anske; Ubink-Bontekoe, Carola Jacoba Maria; Roossien, Folkert Feiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a vector which is capable of the expression of a vascular endothelial growth factor wherein said vector comprises a modified pCMV promoter. The invention further provides use of a vector which is capable of and expressing a vascular endothelial growth factor (VEGF) for the regulation of endothelial function, angiogenesis and arteriogenesis. The invention further comprises use of a vector which is capable of the expression of a vascular endothelial growth factor (VEGF) for the prophylactic treatment of arterial diseases and/or bone marrow diseases and/or neural diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.